ERYTHROMYCIN ETHYLSUCCINATE

SynDRA canonical compound SYN0023129 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	SLC47A1
Mechanism of action	Protein synthesis inhibitor
Indication	amebiasis \| chlamydia \| diphtheria \| erythrasma \| listeria \| pelvic inflammatory disease \| respiratory tract infections \| skin infections \| syphilis
Disease area	infectious disease

All known targets

ABCB1
ALB
CYP3A4
CYP51A1
KCNH2
MLNR
SLC47A1
AOX1
ABCB11
CYP1B1
Abcb11

Mechanisms of action (all sources)

NFKB pathway inhibitor
Motilin receptor agonist
Cytochrome P450 inhibitor
Protein synthesis inhibitor
Bacterial 50S ribosomal subunit inhibitor

Bioactivity evidence (ChEMBL activities table — not curator-asserted)

SLCO1B1
SLCO1B3
CBX1
GMNN

Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)

HXA9
MRGPRX1
NLRP1

Drug classes

Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Gastrointestinal Agents
Protein Synthesis Inhibitors
Macrolide
Macrolide Antimicrobial

ATC classes

S01A · ANTIINFECTIVES
J01F · MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
D10A · ANTI-ACNE PREPARATIONS FOR TOPICAL USE

Cross-references

PubChem CID: 443953
ChEMBL: CHEMBL1200688
ChEBI: CHEBI:31555
KEGG: C12796
RxNorm: 4056
LINCS BRD: BRD-K51677086

Synonyms

Reported adverse events

Stevens-Johnson syndrome
Skin reaction
Pseudomembranous colitis
Hepatitis
Angioedema
Cough
Crystalluria
Headache
Leukopenia
Tachycardia

Look up ERYTHROMYCIN ETHYLSUCCINATE in the interactive SynDRA portal →